Kornimate/medical-research-clean huggingface dataset:
monitoring risks for hematological changes in gas station workers

Conditions: Hematologic Diseases

Summary: gas station workers are exposed to carcinogenic substances.this increases risk of their exposure to hematological diseases such as lymphoblastic leukemia (all), chronic lymphocytic leukemia (cll), myelodysplastic syndromes (mds), and myelogenous leukemia (aml), as well as different forms of non-hodgkin's lymphoma (nhl) and multiple myeloma. thus, the early identification of this condition between the gas station workers may prevent the hematological disease progression.

gas station workers are exposed to carcinogenic substances.this increases risk of their exposure to hematological diseases such as lymphoblastic leukemia (all), chronic lymphocytic leukemia (cll), myelodysplastic syndromes (mds), and myelogenous leukemia (aml), as well as different forms of non-hodgkin's lymphoma (nhl) and multiple myeloma. it is known that severe bone marrow dysplasia is frequently accompanied by early alterations in the immune system and in peripheral cell subsets. the bone marrow injury by benzene metabolites is a strong predisposing factor in the pathogenesis of benzene-induced hematopoietic disease .thus, the early identification of this condition between the gas station workers may prevent the hematological disease progression. the reactive metabolite of benzene, 1,4-benzoquinone (bq) is suggested to be a key molecule of benzene-induced hematotoxicity and carcinogenicity as it cause abnormal accumulation of myeloid cells and precursors, which cause benzene induced cytopenia and myeloid dysplasia in humans.

Eligibility criteria:
inclusion criteria: * this study will be conducted on a group of gas station workers exposed to benzene for more than 3 years . exclusion criteria: * diagnosed gas station workers with blood malignancies . * gas station workers exposed to benzene for less than 3 years .
prospectively predict the efficacy of treatment of gastrointestinal tumors based on peripheral multi-omics liquid biopsy

Conditions: Advanced Gastric Adenocarcinoma; Immunotherapy

Summary: to vertify the function of ev-score on predicting \& monitoring immunotherapeutic outcomes of gc

our previous work identified four plasma ev-derived proteins and combined them to generate a signature score that robustly predicting immunotherapeutic outcomes at baseline and dynamically monitoring disease progressions along with the whole treatment. hence in this stuty, we plan to recruit a prospective cohort to support our conclusions, and provide possible method to realize predicting and monitoring immunotherapeutic outcomes of gc.

Eligibility criteria:
inclusion criteria: * having signed informed consent * age≥ 18 years old * histologically confirmed gastric adenocarcinoma * unresectable recurrent or metastatic disease * measurable disease according to the recist criteria * life expectancy of ≥3 month * no prior chemotherapy of the study more than 4 weeks * immunotherapy regimens were included in the treatment exclusion criteria: * other previous malignancy within 5 year * surgery (excluding diagnostic biopsy) within 4 weeks prior to study * pregnancy or lactation period * legal incapacity

Keywords: plasma-based liquid biopsy protein biomarker extracellular vesicles protein biomarker
community acquired pneumonia in older adults

Conditions: Pneumonia; Aspiration Pneumonia

Summary: this study will utilize diagnostic imaging and salivary biomarkers to estimate the prevalence of aspiration in older adults with suspected community-acquired bacterial pneumonia (cabp). 150 participants over the age of 60 diagnosed with pneumonia will be recruited into this study. 62 of these participants will be enrolled in a supplemental study.

pneumonia is the most common infectious cause of mortality in older adults. standard practice for older adults with pneumonia involves hospitalization and antibiotics. however, recent studies suggest that a significant portion of suspected community-acquired bacterial pneumonia (cabp) cases may actually be due to distinct, dysphagia-related aspiration syndromes (e.g. aspiration pneumonia, pneumonitis). the main study will will assess whether salivary biomarkers (viscoelasticity, substance p) and swallowing function tests can be used to help differentiate cabp from aspiration-related syndromes. the following aims will be completed: * aim 1: compare salivary properties and health outcomes among older adults with aspiration related pneumonia mimics and those with infectious pneumonia * aim 2: compare appearance of lung ultrasound findings among older adults with aspiration related pneumonia mimics and those with infectious pneumonia. * aim 3: describe dysphagia screening results, patient reported swallowing function, salivary properties, oral/nasopharyngeal microbiome profiles, in older adults with pneumonia presenting to the ed. * aim 4: assess the potential impact of the memed bv® test's result on patient management decision making, including antibiotic prescribing and disposition. a supplemental study will be the first to utilize diagnostic imaging (videofluoroscopic evaluation of swallowing and radionuclide salivagram) to estimate the prevalence of aspiration in older adults with suspected cabp. * aim 1: determine the prevalence of dysphagia-related aspiration among older adults with pneumonia.

Eligibility criteria:
emergency department (ed) recruitment inclusion criteria: * 60 years of age or older * patient has clinical criteria for pneumonia or is being treated for pneumonia as defined by abnormal chest imaging or receiving antibiotics for a chest infection or the provider thinks the patient has pneumonia or is planning to treat the patient for pneumonia. * patient is clinically stable and able to safely drink water, per the emergency department provider * ability to provide consent or the presence of a legally authorized representative (lar) who can consent on behalf of the patient exclusion criteria: * prisoner * non-english speaking * respiratory symptoms for 7 days or more phone recruitment inclusion criteria: * 60 years of age and older * patient was diagnosed with or treated for pneumonia at uw health in the past 6 months * ability to provide consent or the presence of a legally authorized representative (lar) who can consent on behalf of the patient exclusion criteria: * prisoner * non-english speaking
using a novel classification system in intravenous gcs therapy of tao: a multi-central, randomized, open, superior trial

Conditions: Thyroid Associated Ophthalmopathy

Summary: for patients with active moderate-to-severe thyroid associated ophthalmopathy (tao), the intravenous glucocorticoids (gcs) is the recommended therapy. however, the efficacy of gcs is not satisfied. investigators established a novel classification of tao for the first time to assess more precisely for better personal treatment.

tao is one of most common extra thyroid manifestation of dysfunctional thyroid disease. since the morbidity of tao has been increasing rapidly, investigators' team is intended to verify the feasibility of the new type of classification system established by the related parameters of orbital mri scan. based on classification, investigators compare the efficacy of two gcs therapy. according to mri,investigators measure the optimal t2 signal intensity ratio (sir) for the treatment of tao, which may help to find a better treatment time for therapy.

Eligibility criteria:
inclusion criteria: 1. the diagnostic standard of tao is according to bartley's criteria. 2. patients with active moderate-to-severe tao based on 2016 eugogo guidelines. 3. cas≥3/7. 4. none of the patients received any glucocorticoids therapy or orbital radiotherapy in the previous 3 months. exclusion criteria: 1. nospecs is 0 or 1.only signs,no symptoms.signs include:reduced blink(stellwag symptoms),two reduced cohesion(mobius levy),moving slowly on the eyelids(von graefe sign),to the point of view,the forehead wrinkled skin should not(joffroyv levy). 2. suffering from other eye diseases or wearing contact lenses. 3. suffering from other autoimmune diseases. 4. acute and chronic infectious diseases. 5. diabetic retinopathy or hypertensive fundus lesions. 6. patients received orbital decompression or other orbital surgery. 7. suffering from eye trauma or ocular surface disease. 8. special occupants, and the working environment has obvious air pollution etc.
investigation into the effects of krill oil vs. fish oil on markers of cardiovascular disease

Conditions: Metabolic Syndrome

Summary: there is some evidence that dietary supplementation with fish oil has health benefits, especially in respect of some of the known risk factors for cardiovascular (heart) disease such as cardiac arrhythmia. however, supplies of fish oil are limited, and it is desirable to validate alternative sustainable sources of the important omega-3 fatty acid components. it has been suggested that oil from krill, which are small marine crustaceans, may be as effective or possibly more beneficial than fish oil, and may provide a more effective and beneficial supplement. dietary management of cardiovascular health parameters (such as blood lipids)is becoming more and more important as the rising trends in obesity nationally and worldwide are leading to escalating incidence of diabetes and heart disease. the investigators propose to use some specific novel lipid measurements of cardiovascular risk to test this possibility in a group of men who, although generally healthy, show some risk factors in terms of their weight and metabolic profile.this pilot study will provide preliminary data to show whether krill oil has similar or different effects from fish oil on the cardiovascular health of overweight but otherwise healthy men, and in particular will provide detailed information on alterations in novel lipid markers of cardiovascular disease, which may be a better diagnostic tool than classical lipid measurements (e.g. serum cholesterol). the investigators have been developing and validating new techniques to measure emerging lipid markers of cardiovascular risk accurately and will continue to develop and investigate these techniques during the course of this project. the investigators hypothesise that krill oil will be more efficacious in reducing markers of risk relating to cardiovascular disease.


Eligibility criteria:
inclusion criteria: * waist circumference ≥ 94cm plus any two of the below: * raised triglycerides : ≥ 150 mg/dl (1.7 mmol/l) * reduced hdl cholesterol: \< 40 mg/dl (1.03 mmol/l) * raised blood pressure: ≥ 130/85 mm hg * raised fasting plasma glucose: ≥ 100 mg/dl (5.6 mmol/l) exclusion criteria: * drug treatment for cardiovascular disease or diabetes, * currently taking fish oil supplements * individuals who would require carers or guardians to make decisions * known history of liver disease

Keywords: males metabolic syndrome otherwise healthy
ultrasound evaluation of preventive measures for postoperative lung atelectasis after surgery

Conditions: Pulmonary Atelectasis, Postoperative

Summary: the aim of this prospective randomized blinded clinical study will be to assess the ultrasound evaluation of different preventive measures of post operative lung atelectasis in abdominal surgeries; these measures include ventilation and fluid measures

ultrasound evaluation for application of different preventive measures of post operative lung atelectasis, including positive end-expiratory pressure, lung recruitment maneuvers, and restrictive fluid management.

Eligibility criteria:
inclusion criteria: * asa physical status i or ii, of either gender. * bmi \< 40 * age 30-60 years * scheduled for elective abdominal surgeries exclusion criteria: * patient refusal * american society of anesthesiologists (asa) physical status classification system more than ii * bmi \> 40 . * psychiatric disorders * history of chest disorders such as asthma and obstructive pulmonary disease (copd). * history of previous thoracic procedures. * pregnancy

Keywords: lung ultrasound lung atelectasis atelectasis pulmonary atelectasis pressure controlled ventilation - volume guarantee (pcv- vg) positive end-expiratory pressure (peep) lung recruitment maneuver restrictive fluid strategies
bioequivalency study of losartan potassium 100 mg tablet under fed conditions

Conditions: Hypertension

Summary: the objective of this study was to prove the bioequivalence of losartan potassium 100 tablet under fasted conditions.


Eligibility criteria:
inclusion criteria: * no clinically significant abnormal findings on the physical examination, medical history, or clinical laboratory results during screening exclusion criteria: * positive test for hiv, hepatitis b, or hepatitis c. * treatment with known enzyme altering drugs. * history of allergic or adverse response to losartan potassium or any comparable or similar product.
bio-availability of rectal artesunate in children with severe falciparum malaria

Conditions: Malaria

Summary: the study aims at describing the pharmacokinetic properties of rectal artesunate in well characterized severely ill patients using intravenous artesunate as a comparator.

individually randomized, open label, 2-arm, cross-over, clinical trial. patients are allocated to receive rectal artesunate at admission and intravenous artesunate after 12 hours or intravenous artesunate at admission and rectal artesunate after 12 hours. all patients are treated for severe malaria with intravenous quinine. frequent blood samples are taken at fixed intervals after the administration of the first and the second dose of study drug. the time frame is 24 hours and thereafter patients continue the standard antimalarial therapy.

Eligibility criteria:
inclusion criteria: * weight ≥6 kilograms and ≤ 34 kilograms * severe malaria (who guidelines 2013; appendix 1) * p. falciparum infection confirmed by rapid diagnostic test (p. falciparum monoinfection or mixed infection with p. ovale or p. malariae) * parents or guardian signed informed consent exclusion criteria: * acute diarrhoea defined as \> 3 liquid stools in the previous 24 hours * visible anorectal malformations or a disease of the rectum * known hypersensitivity to quinine or artesunate * a documented history of an effective dose of parenteral antimalarial in the preceding 24 hours or a single dose of rectal artesunate in the previous 12 hours or a dose of an artemisinin based combination therapy in the previous 6 hours * co-morbidity which in the judgement of the investigator would interfere with the patient treatment or results of the study or place the subject at undue risk * participation in another clinical trial or earlier in the same clinical trial
seroquel on glucose metabolism

Conditions: Schizophrenia

Summary: the purpose of this study is to determine whether six months treatment with the antipsychotic medicine seroquel (quetiapine) may affect the schizophrenic patient's glucose metabolism


Eligibility criteria:
inclusion criteria: * in- or outpatients with schizophrenia, 18-65 years old, requiring a change in treatment due to insufficient efficacy or tolerability and giving signed informed consent. exclusion criteria: * known diabetes mellitus, high hba1c, fasting plasma glucose and/or high 2h glucose-ogtt. * previous use of atypicals (3 months) or other medications that might influence glucose metabolism * contraindications or non-responsiveness for any of the treatments or other safety issues * expected non-compliance to treatment and/or study procedures

Keywords: schizophrenia
an efficacy and safety study of ph-10 aqueous hydrogel for the treatment of plaque psoriasis

Conditions: Psoriasis

Summary: ph-10 is an aqueous hydrogel formulation of rose bengal disodium (rb) for topical administration to the skin, and is being studied for the treatment of cutaneous skin disorders, specifically psoriasis and atopic dermatitis. this phase 2 efficacy and safety study will assess topical ph-10 applied once daily to areas of mild to moderate plaque psoriasis.


Eligibility criteria:
inclusion criteria: * men or women, age 18 or older. * presence of mild to moderate plaque psoriasis on the trunk or extremities (excluding palms, soles, scalp, and facial or intertriginous areas). * fitzpatrick skin type i-vi. * written informed consent by the subject or legal guardian. exclusion criteria: * women of childbearing potential who are pregnant, attempting to conceive, not using effective contraception, or who are nursing an infant. * subjects who have received puva or systemic antipsoriatic therapy (immunosuppressants, cytostatics, corticosteroids) within 28 days of study initiation (two weeks for methotrexate). * subjects who have received uvb light therapy within 14 days of study initiation. * subjects who have received topical antipsoriatic therapy (including corticosteroids, tar, anthralin or vitamin d analogs) to the study plaque areas within 14 days of study initiation. * subjects who have received agents posing a clinically significant risk of photosensitivity reaction within 5 half-lives of study initiation. * subjects who have received any approved or investigational biologic drug therapy for psoriasis within 90 days or 5 half-lives of study initiation. * subjects who have participated in a clinical research study within 28 days of study initiation. * subjects with a history of porphyria, systemic lupus erythematosus or xeroderma pigmentosum. * subjects with clinical conditions that, in the opinion of the investigator may pose a health risk to the subject by being involved in the study or detrimentally affect regular follow-up of the subject.
comparison of standard versus low bicarbonate hemodialysis

Conditions: Chronic Kidney Disease; Metabolic Acidosis

Summary: this study will compare acid-base changes during hemodialysis treatments with a standard dialysis bath versus a lower bicarbonate dialysis bath, and aims to define the factors that limit equilibration of the bicarbonate concentration in a patient's blood with that in the dialysate.


Eligibility criteria:
inclusion criteria: * receiving chronic thrice-weekly conventional hemodialysis for at least 3 months * age \> 18 years exclusion criteria: * use of oral alkali within the previous month * hospitalization within the previous month * inability to provide written informed consent * pregnancy

Keywords: bicarbonate dialysis
asa plavix feasibility study with watchman left atrial appendage closure technology

Conditions: Atrial Fibrillation

Summary: the purpose of the study is to characterize the performance of the watchman laa closure device in atrial fibrillation patients for which long term warfarin therapy is contraindicated.


Eligibility criteria:
inclusion criteria: * 18 years of age or older * paroxysma, persistent, or permanent non-vlavular atrial fibrillation * contraindicated to warfarin * eligible for clopidogrel, ticlopdine, heparin, or aspirin * chads score 1 or greater exclusion criteria: * nyha class iv * laa obliteration * heart transplant * lvef less than 30% * greater than 50% carotid stenosis

Keywords: af atrial fibrillation laa occlusion
association between different blood groups and sepsis in preterm infants

Conditions: Blood Group Antigen Abnormality; Prematurity; Sepsis

Summary: to investigate whether there is a relationship between sepsis and blood groups in preterm infants.this retrospective cohort study included preterm neonates born at \<32 weeks of gestation with a birth weight \<1500 g. neonates were grouped by blood type (o, a, b, ab) and sepsis were compared among these groups.

this retrospective study was conducted on data collected between 1 january 2011 and 31 august 2018 in the neonatal intensive care unit (nicu) of the health sciences university zekai tahir burak women's health education and research hospital. neonates born at ga \<32 weeks with birth weight (bw) \<1500 g were included in the study. data pertaining to the neonates were recorded from medical records for each patient, and their abo blood type was recorded. the neonates were grouped by blood type (o, a, b, ab) and also separated into non-o (a, b, ab) and o groups and non-a (o, b, ab) and a groups for comparison of early and late onset sepsis.

Eligibility criteria:
inclusion criteria: * preterm neonates born at \<32 weeks of gestation with a birth weight \<1500 g. exclusion criteria: * neonates born with severe congenital defects, birth weight ≥1500 g and gestational age ≥32 weeks were excluded.

Keywords: blood group sepsis preterms
autologous cd8+ t-cells expressing an anti-bcma car in patients with myeloma

Conditions: Multiple Myeloma

Summary: this phase i study will test the safety and anti-myeloma activity of ascending doses of descartes-08 (autologous cd8+ t-cells expressing an anti-bcma chimeric antigen receptor) in eligible patients with active multiple myeloma.


Eligibility criteria:
inclusion criteria (condensed): * multiple myeloma that is double-refractory to a proteasome inhibitor (pi) and an immunomodulatory drug (imid) after at least 2 prior lines of therapy or have failed at least 3 prior lines of therapy * measurable disease activity as indicated by serum or urine m-protein, serum free light chain, biopsy-proven plasmacytoma, \>5% bone marrow plasma cells. * adequate vital organ function as indicated by anc (\>1000/ul), platelet count (\>50,000/ul), hemoglobin (\>8 g/dl), serum alt and ast (each \ 30 ml/min), and cardiac ejection fraction (\>45%) exclusion criteria (condensed): note: prior anti-bcma or car-t therapy is not exclusionary * active plasma cell leukemia * pregnant or lactating * active, uncontrolled infection * active and severe auto-immune disease * active arrhythmia, or obstructive or restrictive pulmonary disease * central nervous system disease

Keywords: descartes-08 car t cell cart car-t car t-cell multiple myeloma bcma b-cell maturation antigen b cell maturation antigen